Efficacy and safety of low-dose TBI combined MAC regimen for HSCT in high-risk AML patients with active disease
The FACT regimen is an effective myeloablative conditioning (MAC) strategy for high-risk AML patients, potentially reducing relapse risk without increasing NRM, warranting further research.
Authors
- Shenxian Qian (ORCID: https://orcid.org/0000-0003-1026-4395)
- Ying Xu (ORCID: https://orcid.org/0009-0004-9749-0006)
- C Chen (ORCID: https://orcid.org/0009-0003-9435-0596)
- Kuang Chen (ORCID: https://orcid.org/0000-0001-6618-2255)
- Fan Yang (ORCID: https://orcid.org/0009-0008-5468-4782)
- Junfeng Tan
- Yaping Xie (ORCID: https://orcid.org/0000-0001-9768-3730)
- Lirong Liu (ORCID: https://orcid.org/0000-0002-9102-6446)
- Pengfei Shi (ORCID: https://orcid.org/0000-0002-2966-1676)
- Xilian Huang
- Daquan Gao
Institutions
- Westlake University (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1080/07853890.2024.2446692
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China